Evidence map›Paper›PMID 29861861›Full record

ArticleOncotarget2018

Aberration hubs in protein interaction networks highlight actionable targets in cancer.

Mehran Karimzadeh, Pouria Jandaghi, Andreas I Papadakis, Sebastian Trainor, Johan Rung, Mar Gonzàlez-Porta, Ghislaine Scelo, Naveen S Vasudev, Alvis Brazma, Sidong Huang and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. On the Origin of Biomolecular Networks.Frontiers in genetics · 2019
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Mehran KarimzadehDepartment of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
Pouria JandaghiDepartment of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
Andreas I PapadakisDepartment of Biochemistry, The Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, QC H3G 1Y6, Canada.
Sebastian TrainorLeeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds, LS9 7TF, UK.
Johan RungEuropean Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, CB10 1SD, UK.
Mar Gonzàlez-PortaEuropean Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, CB10 1SD, UK.
Ghislaine SceloInternational Agency for Research on Cancer (IARC), Lyon, 69008, France.
Naveen S VasudevLeeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds, LS9 7TF, UK.
Alvis BrazmaEuropean Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, CB10 1SD, UK.
Sidong HuangDepartment of Biochemistry, The Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, QC H3G 1Y6, Canada.
Rosamonde E BanksLeeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds, LS9 7TF, UK.
Mark LathropDepartment of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
Hamed S NajafabadiDepartment of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
Yasser RiazalhosseiniDepartment of Human Genetics, McGill University, Montreal, QC H3A 1B1, Canada.
McGill University and Génome Québec Innovation Centre · CAEuropean Bioinformatics Institute · GBMcGill University · CAMcGill University Health Centre · CASt James's University Hospital · GBCentre International de Recherche sur le Cancer · FRUniversity of Leeds · GBWellcome Trust · GB

Funding

World Health Organization 001
6 · The paper itself

Abstract

Despite efforts for extensive molecular characterization of cancer patients, such as the international cancer genome consortium (ICGC) and the cancer genome atlas (TCGA), the heterogeneous nature of cancer and our limited knowledge of the contextual function of proteins have complicated the identification of targetable genes. Here, we present Aberration Hub Analysis for Cancer (AbHAC) as a novel integrative approach to pinpoint aberration hubs, i.e. individual proteins that interact extensively with genes that show aberrant mutation or expression. Our analysis of the breast cancer data of the TCGA and the renal cancer data from the ICGC shows that aberration hubs are involved in relevant cancer pathways, including factors promoting cell cycle and DNA replication in basal-like breast tumors, and Src kinase and VEGF signaling in renal carcinoma. Moreover, our analysis uncovers novel functionally relevant and actionable targets, among which we have experimentally validated abnormal splicing of spleen tyrosine kinase as a key factor for cell proliferation in renal cancer. Thus, AbHAC provides an effective strategy to uncover novel disease factors that are only identifiable by examining mutational and expression data in the context of biological networks.

Indexed as

cancercomputational biologygenomicssystems biologytarget discovery

Identifiers

PMID29861861
PMCPMC5982744
OpenAlexW2803449438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.